Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Phase 1a/1b Open Label Dose-escalation/Dose-expansion Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors

Phase 1a/1b Open Label Dose-escalation/Dose-expansion Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors
Conditions:   Solid Tumor;   Microsatellite-stable Colorectal Cancer (MSS CRC);   Adenocarcinoma of the Lung;   Squamous Cell Carcinoma of Head and Neck;   Bladder Cancer;   Triple Negative Breast Cancer;   Gastric Cancer
Interventions:   Drug: TPST-1495;   Drug: Pembrolizumab
Sponsor:   Tempest Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 15, 2020 / by / in
Comments